BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
62.87
+0.13 (0.21%)
Apr 25, 2025, 12:36 PM EDT - Market open
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
$938,788
Profits / Employee
$140,414
Market Cap
12.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,040 | -361 | -10.61% |
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BMRN News
- 8 days ago - BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - PRNewsWire
- 21 days ago - BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion - Seeking Alpha
- 23 days ago - BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PRNewsWire
- 5 weeks ago - BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 2 months ago - BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA - PRNewsWire
- 2 months ago - BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors - PRNewsWire
- 2 months ago - Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
- 2 months ago - BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript - Seeking Alpha